Figure 2.
Analysis of Runx1R188Q/+ BM HSPCs using Sca-1 and CD86 markers and cytokine profiling. (A) BM cellularity of WT and Runx1R188Q/+ mice. (B-C) Immunophenotypic analysis of BM HSPCs using Sca1 and CD86, including LKS+ and LK86+ (B), and LT-HSCs, ST-HSCs, and MPPs (C); (D-E) Quantification of Sca1 protein levels in cell membrane (median fluorescence intensity [MFI], D), and transcript (Ly6a) levels € in LKS+ cells. (F) Representative flow cytometry plots for the analysis of LKS and LK86 marked HSPCs; blue shade represents LK86+ (left panels) and LKS+ (right panels). (G) Relative expression levels of 25 cytokines in BM fluid (Runx1R188Q/+/WT; n = 6 per group). (H-I) Quantification of number of myeloid progenitor cells using Sca-1 (LKS-) and CD86 (LK86-) markers (H), and in common myeloid progenitor (CMPs), GMPs, and MEPs (I). ∗P < .05, ∗∗P < .005; ns, not significant.

Analysis of Runx1R188Q/+ BM HSPCs using Sca-1 and CD86 markers and cytokine profiling. (A) BM cellularity of WT and Runx1R188Q/+ mice. (B-C) Immunophenotypic analysis of BM HSPCs using Sca1 and CD86, including LKS+ and LK86+ (B), and LT-HSCs, ST-HSCs, and MPPs (C); (D-E) Quantification of Sca1 protein levels in cell membrane (median fluorescence intensity [MFI], D), and transcript (Ly6a) levels € in LKS+ cells. (F) Representative flow cytometry plots for the analysis of LKS and LK86 marked HSPCs; blue shade represents LK86+ (left panels) and LKS+ (right panels). (G) Relative expression levels of 25 cytokines in BM fluid (Runx1R188Q/+/WT; n = 6 per group). (H-I) Quantification of number of myeloid progenitor cells using Sca-1 (LKS-) and CD86 (LK86-) markers (H), and in common myeloid progenitor (CMPs), GMPs, and MEPs (I). ∗P < .05, ∗∗P < .005; ns, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal